News
Virtual screening is being hailed by some as a superior method of evaluating compounds compared to high throughput screening. However, it’s still important to choose wisely between a ligand- or protein-based model template, as both are prone to mishandling.
In the June issue of Innovations in Pharmaceutical Technology, Cresset’s Tim Cheeseright and Rob Scoffin discuss virtual screening as a proven technology that can replace large-scale HTS runs in order to create a more focused data set for a smaller-scale screen.
Read the article in IPT, pages 16 to 19.
The pharmaceutical and biotech sectors suffer more data security breaches than any other industry, with 53% resulting from malicious activity. To protect against potential ...
Force fields provide critical infrastructure underlying a broad range of molecular modeling for drug discovery. Learn more in this recent ...
A chance to catch up on Professor Julien Michel's presentation at this recent Boston Area Group for Informatics and Modeling ...